Groupe hospitalier Diaconesses Croix Saint Simon
Paris, 75020, France
NCT Number: NCT07755462
Background and Rationale:
Injury to the tibiofibular syndesmosis in ankle fractures is a major prognostic factor for the development of post-traumatic osteoarthritis. The syndesmosis is frequently involved when posterior tibial marginal fragments are fractured. Intraoperative stability testing determines whether a trans-syndesmotic device (screws, endobutton, or plate) is required. However, trans-syndesmotic devices carry risks such as malreduction, hardware removal, and infection. Anatomical fixation of posterior tibial fragments is hypothesized to restore syndesmotic stability, thereby reducing the reliance on trans-syndesmotic implants. Objective and Hypothesis:
The primary objective of this randomized controlled trial is to compare the rate of trans-syndesmotic stabilization device usage between patients undergoing osteosynthesis of posterior marginal fragments and those managed without posterior fragment osteosynthesis. The hypothesis is that syndesmotic stability (defined as non-use of a trans-syndesmotic device intraoperatively) will be significantly higher in the posterior fragment fixation group. Study Design:
Multicenter, open-label, randomized, two-arm parallel-group trial conducted at two orthopedic trauma centers (Groupe Hospitalier Diaconesses Croix Saint-Simon and Hôpital Lariboisière).
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Interventional
Not applicable
Paris, 75020, France
Study Flow and Procedures:
Screening and Randomization: Eligible patients presenting with recent bimalleolar ankle fractures (< 3 weeks) involving the posterior marginal fragment and syndesmosis (Bartoníček types 2, 3, or 4) are identified in the emergency/trauma department. Following written informed consent, participants are randomized into Group 1 (posterior marginal fragment osteosynthesis) or Group 2 (no posterior fragment osteosynthesis).
Preoperative Assessment: Comparative bilateral ankle X-rays and CT scans to confirm fracture classification and baseline metrics (fragment thickness > 2 mm, height > 6 mm).
Intraoperative Phase: Surgical management of the bimalleolar fracture according to assigned group. Intraoperative stress testing of the syndesmosis is performed to evaluate stability and record the necessity of trans-syndesmotic device placement.
Postoperative Follow-up: Day 1 to Week 6: Comparative bilateral CT scan to evaluate fragment and syndesmosis reduction. 3 Months & 12 Months: Clinical follow-up visits including comparative weight-bearing X-rays, evaluation of AOFAS score, and patient-reported questionnaires (MOXFQ, SF-12).
Postoperative complications (infections, neuropathic pain, fibular pain, flexor hallucis longus tendonitis) are systematically recorded throughout the 12-month follow-up.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Surgical management of bimalleolar ankle fractures with osteosynthesis of the posterior fragments
Surgical management of bimalleolar ankle fractures without osteosynthesis of the posterior fragments.
Time frame: ntraoperative (Day 0)
Proportion of patients requiring the intraoperative placement of a trans-syndesmotic stabilization device (such as a screw, endobutton, or plate) to achieve syndesmotic stability, as assessed during surgery following stress testing.
Time frame: 3 months and 12 months postoperatively
Clinical and functional assessment score combining pain, function, and alignment. The total score ranges from 0 to 100 points, where 0 represents severe disability/pain and 100 represents optimal function and no pain. Higher scores indicate better clinical outcome.
Time frame: 3 months and 12 months postoperatively
Patient-reported outcome measure assessing foot/ankle pain, walking/standing difficulties, and social interaction. The metric is converted to a score ranging from 0 to 100, where 0 represents no symptoms/best health state and 100 represents severe impairment. Higher scores indicate worse symptoms.
Time frame: 3 months and 12 months postoperatively
Patient-reported general health survey generating a Physical Component Summary (PCS) and Mental Component Summary (MCS) score. Norm-based scores range from 0 to 100, where higher scores indicate better health status.
Time frame: Between Postoperative Day 1 and Week 6
Assessment of posterior marginal fragment reduction quality and syndesmosis reduction (measuring fibular rotation, anterior and posterior tibiofibular distances, and anteroposterior translation) evaluated on postoperative CT scans.
Time frame: 3 months and 12 months postoperatively
Radiographic assessment of syndesmotic reduction on weight-bearing comparative X-rays, including medial clear space, tibiofibular clear space, tibiofibular overlap, and fibular length.
Time frame: Through 12 months postoperatively
Proportion of patients experiencing surgery-related complications, including surgical site infections, neuropathic pain, fibular pain, or flexor hallucis longus pain.
Groupe Hospitalier Diaconesses Croix Saint-Simon
Other
Acronym: SYNDESMOSE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05019638
Ankle Fractures, Ankle Injuries
Salt Lake City, Utah, United States
View Trial DetailsNCT04113044
Ankle Fractures, Ankle Injuries
Los Angeles, California, United States
View Trial DetailsNCT05185115
Ankle Fractures, Ankle Injuries
Nantes, France
View Trial DetailsNCT04615650
Ankle Fractures, Ankle Injuries
Bærums verk, Akershus, Norway
View Trial Details